Eupraxia Pharmaceuticals (EPRX) Net Margin (2023 - 2025)
Eupraxia Pharmaceuticals' (EPRX) quarterly Net Margin came in at 1881.16% in Q1 2025, down 116747.0% year-on-year from N/an in Q1 2024, and down 163.58% on a QoQ basis from 713.7% in Q1 2024.
Eupraxia Pharmaceuticals (EPRX) Net Margin (2023 - 2025) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has 3 years of Net Margin data on file, last reported at 1881.16% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Eupraxia Pharmaceuticals | 350.77 Mn | 350.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -1,881.16% |
| Mar 31, 2024 | -713.70% |
| Mar 31, 2023 | 3,087.03% |